As part of the largest model project in Germany in accordance with § 64b SGB V at the Pfalzklinikum, a clearing concept was developed in the Clinic for Geriatric Psychiatry to ensure rapid and adequate diagnosis and effective referral to the further treatment setting. Retrospective data of all clearing cases from the first year are presented. In addition to demographic data and treatment diagnoses, the distribution of patients across settings providing further treatment is presented.From a total of 1076 cases, more than half of the patients were able to be treated or discharged as outpatients after five working days at the latest.The results emphasize the central role of clearing for treatment management. With regard to demographic change, suggestions for standard care can be derived in order to provide patients with special diagnostic and treatment needs with more targeted and resource-efficient care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2495-8328 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Autonomous University of Barcelona, Barcelona, Catalonia, Spain.
Background: Alzheimer's and related disorders (ADRD) represent a range of neurodegenerative conditions characterized by abnormal protein deposits in the brain. Despite advances, there is a need for enhanced diagnostic and treatment approaches that acknowledge the diversity of ADRD. This project introduces the Alzheimer's and Related Disorders Multicenter Archive (ARMA), a collaborative platform with an advanced Electronic Data Capture (EDC) system linked to Electronic Medical Records (EMR) designed to refine ADRD diagnosis and natural history understanding, thus informing precision medicine.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, USA.
Background: Benfotiamine, a prodrug of thiamine, raises blood levels by 50-100 times to achieve pharmacologic effects. It provides a novel therapeutic direction addressing a well-characterized brain tissue thiamine deficiency and related changes in glucose metabolism in AD. BenfoTeam is a seamless phase 2A-2B "proof of concept" (POC), double-blind, placebo-controlled RCT investigating tolerability, safety, and efficacy of benfotiamine, as a first-in-class small molecule treatment for early AD.
View Article and Find Full Text PDFBackground: Reliable treatment approaches for addressing early cognitive impairment and Alzheimer's disease (AD) are currently lacking. Given the multifactorial nature of AD, therapeutic strategies need to focus on disease-specific biochemical pathways. Given the significance of metabolic pathways in cognitive impairment, it is essential to investigate alternative disease modifiers capable of targeting multiple metabolic pathways, such as phytochemicals.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
UIPS, CHANDIGARH, Punjab, India.
Background: Alzheimer's disease is a brain disorder that causes neurodegeneration and is linked with insulin resistance at molecular, clinical, and demographic levels. Defective insulin signaling promotes Aβ aggregation and accelerates Aβ formation in the brain leading to Type III diabetes.
Objective: The objective of this research project is to demonstrate a linkage if any between the risk of developing Alzheimer's disease and insulin resistance.
Background: Dementia, a growing health crisis, disproportionally affects persons from racial/ethnic backgrounds and individuals with comorbidities. Latelife change in cognition is complex and nonlinear, as well as differential for these individuals. These individuals are also largely underrepresented in clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!